Viridian Therapeutics, Inc./DE Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Viridian Therapeutics, Inc./DE (VRDN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$595.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$595.00K.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.00M, a 494.12% decline year-over-year.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $84.00K.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $294.00K, a 80.07% decline year-over-year.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $457.00K.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$348.00K, a 147.80% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $728.00K.
- Viridian Therapeutics, Inc./DE other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$233.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$595.00K 10-Q · filed 2026-08-06 | -$1.60M 10-Q · filed 2026-08-06 | -$1.52M derived: sum of 3 quarters · filed 2026-08-06 | -$1.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.00M 10-Q · filed 2026-05-05 | -$921.00K derived: sum of 2 quarters · filed 2026-05-05 | -$627.00K derived: sum of 3 quarters · filed 2026-05-05 | -$803.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $378.00K derived: sum of 2 quarters · filed 2026-02-26 | $202.00K derived: sum of 3 quarters · filed 2026-08-06 | $457.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $294.00K 10-Q · filed 2025-11-05 | $118.00K derived: sum of 2 quarters · filed 2026-08-06 | $373.00K 10-Q · filed 2025-11-05 | -$569.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$176.00K 10-Q · filed 2026-08-06 | $79.00K 10-Q · filed 2026-08-06 | -$863.00K derived: sum of 3 quarters · filed 2026-08-06 | $612.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $255.00K 10-Q · filed 2026-05-05 | -$687.00K derived: sum of 2 quarters · filed 2026-05-05 | $788.00K derived: sum of 3 quarters · filed 2026-05-05 | $612.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$942.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $533.00K derived: sum of 2 quarters · filed 2026-02-26 | $357.00K derived: sum of 3 quarters · filed 2026-02-26 | -$348.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.48M 10-Q · filed 2025-11-05 | $1.30M derived: sum of 2 quarters · filed 2025-11-05 | $594.00K 10-Q · filed 2025-11-05 | $996.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$176.00K 10-Q · filed 2025-08-06 | -$881.00K 10-Q · filed 2025-08-06 | -$479.00K derived: sum of 3 quarters · filed 2026-02-26 | -$370.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$705.00K 10-Q · filed 2025-05-06 | -$303.00K derived: sum of 2 quarters · filed 2026-02-26 | -$194.00K derived: sum of 3 quarters · filed 2026-02-26 | -$193.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $511.00K derived: sum of 2 quarters · filed 2026-02-26 | $512.00K derived: sum of 3 quarters · filed 2026-02-26 | $728.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $109.00K 10-Q · filed 2024-11-12 | $110.00K derived: sum of 2 quarters · filed 2024-11-12 | $326.00K 10-Q · filed 2024-11-12 | $876.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $1.00K 10-Q · filed 2024-08-08 | $217.00K 10-Q · filed 2024-08-08 | $767.00K derived: sum of 3 quarters · filed 2025-03-03 | $904.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $216.00K 10-Q · filed 2024-05-08 | $766.00K derived: sum of 2 quarters · filed 2025-03-03 | $903.00K derived: sum of 3 quarters · filed 2025-03-03 | $761.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $687.00K derived: sum of 2 quarters · filed 2025-03-03 | $545.00K derived: sum of 3 quarters · filed 2025-03-03 | -$233.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $137.00K 10-Q · filed 2023-11-13 | -$5.00K derived: sum of 2 quarters · filed 2023-11-13 | -$783.00K 10-Q · filed 2023-11-13 | -$937.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$142.00K 10-Q · filed 2023-08-08 | -$920.00K 10-Q · filed 2023-08-08 | -$1.07M derived: sum of 3 quarters · filed 2024-02-27 | -$1.06M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$778.00K 10-Q · filed 2023-05-10 | -$932.00K derived: sum of 2 quarters · filed 2024-02-27 | -$923.00K derived: sum of 3 quarters · filed 2024-02-27 | -$914.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$145.00K derived: sum of 2 quarters · filed 2024-02-27 | -$136.00K derived: sum of 3 quarters · filed 2024-02-27 | -$149.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $9.00K 10-Q · filed 2022-11-14 | $18.00K derived: sum of 2 quarters · filed 2022-11-14 | $5.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $9.00K 10-Q · filed 2022-08-15 | -$4.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |